TrialESMO open2023

Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial.

M Ferreiro-Pantín et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.